CMV and Immunosenescence: from basics to clinics
Affiliation
Immunology Unit, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Reina Sofia University Hospital-University of Cordoba, Cordoba, SpainImmunology Unit, Department of Physiology, University of Extremadura, Caceres, Spain
University of Michigan, Department of Epidemiology, Center for Social Epidemiology and Population Health, Ann Arbor, Michigan, USA
Division of Infection and Immunity, University College London, London, UK
Infections and Immunity, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
School of Cancer Sciences, University of Birmingham, Birmingham, UK
University of Amsterdam, Amsterdam, The Netherlands
Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
Department of Internal Medicine II, Center for Medical Research, University of Tübingen, Tübingen, Germany
Laboratory of Molecular Immune-Biology, Hospital General Universitario Gregorio Marañón, Madrid and Laboratory of Immunovirology; Infectious Diseases Service, IBiS, Seville, SpainDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USAResearch Center on Aging, Sherbrooke, CanadaRegenerative Medicine Group, Cranfield Health, Cranfield University, Cranfield, UKInstitute for Biomedical Aging Research, University of Innsbruck, Innsbruck, AustriaDepartment of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, USAUniversity of Tampere, Medical School, Tampere, FinlandBrighton and Sussex Medical School, Brighton, UKSingapore Immunology Network, Singapore, SingaporeIMIM (Hospital del Mar Research Institute), Univ. Pompeu Fabra, Barcelona, SpainDepartment of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The NetherlandsUniversity of British Columbia, Vancouver, CanadaDepartment of Clinical Immunology, University Hospital Alexandrovska, Sofia, BulgariaDepartment of Immunobiology and the Arizona Center on Aging, University of Arizona College of Medicine, Tucson, Arizona, USAUniversity of Birmingham, Birmingham, UKDepartment of Internal Medicine and Biomedical Sciences, University of Parma, Parma, ItalyExperimental Immunology, Academic Medical Center, Amsterdam, The NetherlandsDivision of Geriatric Medicine and Gerontology, Biology of Healthy Aging Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAUniversity of Cambridge Department of Medicine Addenbrookes Hospital, Cambridge, UKDepartment of Clinical Immunology and Transplantology, Medical University of Gdansk, Gdansk, PolandMannheim Institute of Public Health, Social and Preventive Medicine (MIPH), University of Heidelberg, Mannheim Medical Faculty, Mannheim, Germany
Issue Date
2012Metadata
Show full item recordPublisher
BioMed CentralCitation
Solana et al. Immunity & Ageing 2012, 9:23 http://www.immunityageing.com/content/9/1/23Journal
Immunity & AgeingRights
© 2012 Solana et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).Collection Information
This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.Abstract
Alone among herpesviruses, persistent Cytomegalovirus (CMV) markedly alters the numbers and proportions of peripheral immune cells in infected-vs-uninfected people. Because the rate of CMV infection increases with age in most countries, it has been suggested that it drives or at least exacerbates "immunosenescence". This contention remains controversial and was the primary subject of the Third International Workshop on CMV & Immunosenescence which was held in Cordoba, Spain, 15-16th March, 2012. Discussions focused on several main themes including the effects of CMV on adaptive immunity and immunosenescence, characterization of CMV-specific T cells, impact of CMV infection and ageing on innate immunity, and finally, most important, the clinical implications of immunosenescence and CMV infection. Here we summarize the major findings of this workshop.EISSN
1742-4933Version
Final published versionAdditional Links
http://www.immunityageing.com/content/9/1/23Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2012 Solana et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).